Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares

* Keros Therapeutics (NASDAQ:KROS [https://seekingalpha.com/symbol/KROS]) has commenced a cash tender offer to repurchase up to $194.4 million of common shares, at a purchase price of $17.75 per share. The Company expects to fund the tender offer from its existing cash and cash equivalents.
* The tender offer, which is a part of its previously announced $375 million capital return program, will expire at 5:00 p.m. ET on Tuesday, November 18, 2025, unless extended or earlier terminated.
* KROS +3.9% premarket to $14.37
* Source: Press Release [https://seekingalpha.com/pr/20271222-keros-therapeutics-commences-issuer-tender-offer-to-repurchase-up-to-194_4-million-shares]

MORE ON KEROS THERAPEUTICS

* Keros Therapeutics: A Potential Dart Throw [https://seekingalpha.com/article/4825839-keros-therapeutics-a-potential-dart-throw]
* Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path [https://seekingalpha.com/article/4815817-keros-therapeutics-orphan-drug-win-for-dmd-candidate-a-small-step-on-right-path]
* Keros jumps on plan to return $375M in excess capital [https://seekingalpha.com/news/4504177-keros-jumps-on-plan-to-return-375m-in-excess-capital]
* Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset [https://seekingalpha.com/news/4487457-keros-gains-orphan-drug-designation-duchenne-muscular-dystrophy-asset]
* Seeking Alpha’s Quant Rating on Keros Therapeutics [https://seekingalpha.com/symbol/KROS/ratings/quant-ratings]